This special issue is dedicated to photodynamics, the diagnostic and therapeutic use of photosensitizers activated by light. Although the roots go back to the late 19th century [1] , in many clinical disciplines photodynamics is still not as well established as researchers would have expected or hoped. In this editorial, we want to shed some light on why this is and whether photodynamic procedures have a more promising future.
Photodynamic diagnosis (PDD) involves exciting and detecting tissue fluorescence from a previously administered photosensitizing drug and drawing diagnostic conclusions from the signals obtained. It is part of a broader range of photodiagnostic techniques (PD), which include autofluorescence, non-phototoxic drug fluorescence (e.g., labeled antibodies) and other ways of interrogating tissue with optical signals and analyzing the emitted signal, such as elastic scattering spectroscopy. PDD overlaps with photodynamic therapy (PDT) in which tissue ablation can be achieved by activating photosensitizers with light, leading to necrosis or apoptosis. The term "photodynamic therapy" dates back to 1904, when Prof. Hermann von Tappeiner was trying to clarify how the mechanism behind the phototoxicity, which he and his student Oscar Raab had discovered in 1897, is different from the photosensitization of photographic plates, which was an important development at that time [2] . There had been heavy disputes between the groups of Prof. Finsen in Copenhagen, Prof. Neisser in Breslau and Prof. von Tappeiner in Munich. None of them knew about triplet states and energy transfer to molecular oxygen. Von Tappeiner considered the fluorescence he had observed with all phototoxic drugs somehow caused the toxic effects. The term "photodynamic" was thus not coined to describe the "dynamic" transition of absorbed energy via intersystem crossing and triplet-triplet energy transfer, but just to discriminate it from "photosensitization".
When a photosensitizer drug is activated by light in tissue, several things can happen, depending on the particular drug and the general conditions. The drug may fluoresce and decay back to the ground state (in PDD), the drug may be photobleached or reactive oxygen species (ROS) such as singlet oxygen may be produced, which are cytotoxic, leading to cell death (in PDT). In the clinical setting, there is some selectivity of uptake of photosensitizers in cancers over a period of time varying from a few minutes to several days. The degree of selectivity varies greatly between different organs and indeed between different parts of individual organs. However, with current technology, the value of this selectivity for achieving selective tumor necrosis is often over emphasized. The main selectivity comes from careful delivery of the therapeutic light to the diseased area.
However, the selectivity of uptake can be enough to be of great diagnostic value, particularly using the photosensitizing pro-drug, 5-aminolaevulinic acid (5-ALA) or one of its esters, which are converted in vivo to the photoactive derivative protoporphyrin IX (PpIX). 5-ALA-based fluorescence-guided resection of malignant gliomas [3] has been approved in many countries but is still pending approval in the USA. The hexyl ester of 5-ALA is approved for localization of early stage or flat malignant or pre-malignant lesions in the urinary bladder [4] . 5-ALA-PDD may also have significant potential for the intra-operative detection of peritoneal metastatic spread and for defining resection margins for a variety of parenchymal cancers.
PDT primarily destroys organelles, cell membranes and other structures in the cytosol -not so much the DNA. The structural integrity of organs is well preserved as connective tissues like collagen are largely unaffected [5] . This is manifest in the remarkably good cosmetic results when used for early skin cancers and pre-cancers. The mode of action is thus very different from any type of radiotherapy. PDT is far less mutagenic, is not limited by cumulative toxicity (unlike radiotherapy, treatment can be repeated at the same site) and does not require handling of radioactive materials.
As used at present, PDT in oncology is primarily a local therapy. However, much research interest now focuses on the ability of the breakdown products of PDT to stimulate a systemic immunological response [6, 7] . This has the potential to treat undetected micrometastases, but much further research on this field is needed.
Outside oncology, PDT has been well established in ophthalmology for more than 10 years for the treatment of age-related macular degeneration. It has recently been superseded by anti-angiogenic therapy but may regain terrain by combination treatments. The largest and most dynamic new area of research is for antimicrobial treatment [8, 9] .
Why is PDT still in its "infancy"? Even where clinical approvals have been obtained, only a minority of centers offers this type of treatment to patients. There are many reasons. Perhaps the most important are: 1. A lack of sufficient clinical evidence of efficacy when compared with conventional therapeutic options. 2. Conservatism of the medical profession. 3. Vested interests that would be challenged by the widespread adoption of PDT. 4. Perceived (but not proven) increased cost.
PDT is not currently an attractive option for pharmaceutical companies. The regulatory hurdles of getting approval for both a drug and a light source are complex and expensive and it is less attractive commercially having a drug that is only given once or a small number of times compared with one that is given regularly over an extended period. However, this could change rapidly if new clinical trials have showed that PDT for common conditions was simpler, more effective, safer and cheaper with a short recovery time, compared with conventional treatment options.
Other problems include the need for treatment planning (drug and light dosimetry), the need for different light sources to match the absorption wavelength peaks of different photosensitizers and the prolonged skin photosensitivity associated with the early photosensitizers, although this is much less of a problem with newer agents.
What will we see in the near future? PDT is well established in dermatology and indications may expand [10, 11] . In various countries, PDT is approved for cancer and pre-cancers of the esophagus, lung, bladder, head and neck, and bile duct, but not used frequently. This may be partly due to equivalent or better alternatives being identified (e.g., radiofrequency ablation of dysplasia in Barrett's esophagus) but also due to the lack of equipment and experience. A phase-III trial is close to completion for PDT of localized prostate cancer (vascular-targeted phototherapy) and may open a new, huge market [12, 13] . Phase-III trials are also in preparation for PDT of cervical (pre-)cancer [14] . PDT is actively under investigation for the treatment of pancreatic cancer [15] .
Scientific and industrial interest in establishing PDT is increasing rapidly in Asia and countries like Brazil where many patients cannot afford the expensive conventional medical treatments available in the Western World.
There are seven papers in this issue, six of them contributing to a better understanding of PDD and PDT. Zvi Malik is a pioneer of 5-ALA for PDD or PDT. He identifies two important fields for further research: (1) new multifunctional 5-ALA-prodrugs, and (2) the need to prove unequivocally that 5-ALA-based PDT does not produce resistance -an important perceived advantage over chemo-or radiotherapy [16] . Wang et al. [17] provide insight into the dermatological applications of PDT in China. Senior author Xiuli Wang has many years of experience using 5-ALA-based PDT for skin lesions including acne and genital warts. This is an important overview of much material previously only published in Chinese.
Alison Curnow and Andrew Pye [18] show that the efficacy of 5-ALA-PDT is enhanced by reducing the availability of the iron required to convert PpIX to haem, which outweighs the reduction in cytotoxicity related to less ROS activation. The number of ROS per cell produced during PDT is the key value which determines the fate of the cell. Timothy Zhu et al. [19] compare calculated and measured necrosis efficiency under different conditions. The unexpected conclusion is that in vivo less ROS per cell are needed than in vitro.
Wolfgang Becker and Vladislav Shcheslavskiy [20] address the fluorescence lifetime of fluorochromes. By measuring this "decay time" (usually in the nanosecond time range) of the excited state of a fluorophore, one can detect whether the fluorophore is free or bound to protein or lipid structures. Mikhail Kleshnin et al. [21] constructed a fluorescence tomograph. They studied epi-illumination (excitation and camera detection from the same side) and transillumination (excitation with synchronous detection from the other side). The transillumination approach yielded better results.
A final article is not directly linked to PDD or PDT. Muhammet Kerim Ayar [22] studied a special type of erbium laser for caries removal with respect to undesired microcrack production and found that these can be avoided by reducing the pulse power and increasing the repetition rate.
The guest editors for this issue are confident that PDD and PDT will eventually become indispensable tools in everyday clinical practice for an increasing number of indications. This issue highlights a few intriguing research aspects, exemplifying the vast potentials photodynamics still has to offer.
At this point, we would like to encourage all of our readers again to submit manuscripts to Photonics & Lasers in Medicine (PLM). We are pleased to announce the 2016 Pater Leander Fischer Prize, which will be awarded to the best PLM publication from the years 2014/2015. The prize is donated by the Deutsche Gesellschaft für Lasermedizin (DGLM) e.V. and is endowed with 1000 euros. Detailed information about the modalities for submission and upcoming issues can be found in the "Call for Papers" in this issue.
Finally, we would like to draw your attention to the next meeting of the DGLM. As part of the LASER World of PHOTONICS Congress and Exhibition, which will be held from 22 to 25 June 2015 at the International Congress Centre Munich, the DGLM is organizing an application panel on the topic "Laser-advanced new methods for diagnostics and therapeutics". So please make a note of the date: June 22, 2015! We are looking forward to your active participation and to interesting discussions.
